A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2001
11/15/2001	DE10022856A1 Treating central nervous system disorders e.g. cognitive deficiency or depression, using combination of lipoic acid and C-1 donor e.g. S-adenosyl-methionine
11/15/2001	CA2409759A1 Method and composition for the treatment of angiogenesis
11/15/2001	CA2409720A1 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
11/15/2001	CA2409679A1 Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy
11/15/2001	CA2409515A1 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
11/15/2001	CA2408935A1 Method of treating immune pathologies with low dose estrogen
11/15/2001	CA2408889A1 Immunosuppressive compositions
11/15/2001	CA2408840A1 Myc targets
11/15/2001	CA2408732A1 Modified es cells and es cell-specific gene
11/15/2001	CA2408666A1 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
11/15/2001	CA2408665A1 Novel regulator of g protein signalling
11/15/2001	CA2408632A1 Ph domain-interacting protein
11/15/2001	CA2408622A1 Methods for inhibiting proliferation and inducing apoptosis in cancer cells
11/15/2001	CA2408576A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/15/2001	CA2408571A1 Mammalian receptor proteins; related reagents and methods
11/15/2001	CA2408549A1 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	CA2408547A1 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	CA2408486A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/15/2001	CA2408297A1 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	CA2408288A1 Novel substituted diamine derivatives useful as motilin antagonists
11/15/2001	CA2408253A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/15/2001	CA2408228A1 Method for promoting neovascularization
11/15/2001	CA2408213A1 Protein complexes and assays for screening anti-cancer agents
11/15/2001	CA2408196A1 Sphingosine kinase and uses thereof
11/15/2001	CA2408166A1 Presenilin enhancers
11/15/2001	CA2408152A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
11/15/2001	CA2408106A1 Opioid antagonist compositions and dosage forms
11/15/2001	CA2408098A1 Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
11/15/2001	CA2408010A1 Identification of neural defects associated with the nucleosomal assembly protein 1l2 gene
11/15/2001	CA2408002A1 Enzymatic assays for screening anti-cancer agents
11/15/2001	CA2407886A1 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
11/15/2001	CA2407864A1 Lipid metabolism enzymes
11/15/2001	CA2407850A1 Cytoskeleton-associated proteins
11/15/2001	CA2407698A1 Repair of nerve damage
11/15/2001	CA2406549A1 R-eliprodil for treating glaucoma
11/15/2001	CA2406512A1 Pharmaceutical compounds for treating copd
11/15/2001	CA2405758A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
11/15/2001	CA2403264A1 Chiral fluoroquinolizinone arginine salt forms
11/14/2001	EP1154019A2 G-protein coupled receptor (HFGAN72X)
11/14/2001	EP1153924A2 Substituted 1,3-oxathiolanes with antiviral properties
11/14/2001	EP1153612A1 Anticancer agent potentiators
11/14/2001	EP1153302A1 Diagnostics and therapeutics for macular degeneration
11/14/2001	EP1153301A1 Diagnostics and therapeutics for arterial wall disruptive disorders
11/14/2001	EP1153133A2 Human diacylglycerol kinase beta (hdagk beta) proteins and nucleotide sequences encoding the same
11/14/2001	EP1153038A1 Therapeutics and diagnostics based on a il-1b mutation
11/14/2001	EP1153036A1 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
11/14/2001	EP1153035A2 Human lipid-associated proteins
11/14/2001	EP1153034A1 Growth hormone secretagogues
11/14/2001	EP1152776A1 Biodegradable, injectable oligomer-polymer composition
11/14/2001	EP1152772A2 Liposome composition and method for administration of a radiosensitizer
11/14/2001	EP1152771A2 Adjuvant and cell maturation agent
11/14/2001	EP1152770A1 Small peptides and methods for treatment of asthma and inflammation
11/14/2001	EP1152764A1 Compositions and methods for use in targeting vascular destruction
11/14/2001	EP1152761A2 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
11/14/2001	EP1152757A2 Connective tissue softening
11/14/2001	EP1152752A1 Methods for preventing graft rejection and ischemia-reperfusion injury
11/14/2001	EP1152734A1 Modified calycins
11/14/2001	EP1152731A1 A skin care composition that mediates cell to cell communication
11/14/2001	EP1152723A1 Enzymatic treatment and prevention of hypertrophic skin
11/14/2001	EP0862431B1 Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate
11/14/2001	EP0777482B1 Combined preparation for the therapy of immune diseases
11/14/2001	CN1322251A Mutant human hepatitis B viral strain and uses thepeof
11/14/2001	CN1322214A Induction of antiobiotic proteins and peptides by LAIT/sCD14-protein
11/14/2001	CN1322139A Agents for retarding change of hormone-dependent cancer into hormone-independent cancer
11/14/2001	CN1322138A Protease inhibitors for use in treatment of psoriasis
11/14/2001	CN1322136A Neuroimmunophilins for selective neuronal radioprotection
11/14/2001	CN1322133A Vitronectin receptor antagonists
11/14/2001	CN1322130A Inhibitors of type 3 3a -hydrosteroid dehydrogenase
11/13/2001	US6316692 Insertion of nucleotide sequences into genomes; inject sample into testes, recover preferential polypeptide from transformed cells
11/13/2001	US6316630 Treating epothilone to deoxygenate the epothilone, and thereby to provide the desoxyepothilone
11/13/2001	US6316601 Antibodies specific for β6 integrins
11/13/2001	US6316504 Administering r(+)-n-propargyl-1-aminoindan or its salt for therapy of multiple sclerosis
11/13/2001	US6316502 Administering disulfide derivative of dithiocarbamate compound to bind to iron
11/13/2001	US6316501 Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
11/13/2001	US6316492 Methods for treating or preventing viral infections and associated diseases
11/13/2001	US6316462 Methods of inducing cancer cell death and tumor regression
11/13/2001	US6316457 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
11/13/2001	US6316455 Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound
11/13/2001	US6316444 SRC kinase inhibitor compounds
11/13/2001	US6316435 Combination therapy for lymphoproliferative diseases
11/13/2001	US6316431 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents
11/13/2001	US6316426 Nucleoside derivative for diabetes, heart disease, cerebrovascular disorders, parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis
11/13/2001	US6316424 Sulfated phosphatidylinositols, their preparation and use of the same
11/13/2001	US6316416 Uteroglobin therapy for epithelial cell cancer
11/13/2001	US6316404 Treatment of non-insulin-dependent diabetes mellitus using an rxr agonist alone or in combination with a ppar.gamma. agonist such as a thiazolidinedione compound.
11/13/2001	US6316403 Deactivation of factor ix for coagulation inhibition and antiischemic agents
11/13/2001	US6316269 Methods for screening drugs to predict tardive dyskinesia
11/13/2001	US6316239 HKABY60 kinase family polypeptides
11/13/2001	US6316237 Respiratory nitrate reductase alpha subunit
11/13/2001	US6316219 Compounds
11/13/2001	US6316203 Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
11/13/2001	US6316196 Methods for analyzing LTC4 synthase polymorphisms and diagnostic use
11/13/2001	US6316027 Fast-dissolving dosage forms for dopamine agonists
11/13/2001	US6316021 Extensible mask including an adhesive matrix that can be stretched at least in the wet state
11/13/2001	US6316012 Cosmetic or pharmaceutical composition comprising, in combination, a peroxidase and an anti-singlet oxygen agent
11/13/2001	US6316007 Combined physical and immunotherapy for cancer
11/13/2001	US6315998 Administering anti-cd40 monoclonal antibody or an antigen binding fragment which is being free of significant agonistic activity and binding to a human cd40 antigen located on surface of a human b cell prevents growth or differentiation
11/13/2001	US6315995 Adding to blood inactive recombinant mutein comprising proteolytically inactive mutein of factor ix or ixa to inhibit clot formation, does not interfere with hemostasis when the blood is administered to a patient
11/13/2001	US6314956 Treating lung defects associated hypoxemia or smooth muscle constriction; administer ethyl nitrite to human and monitor
11/10/2001	CA2347151A1 Method for screening a substance having promoting activity on hair growth

1 ... 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 ... 1151